Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 50 microgram/ml - oral liquid - excipient ingredients: methyl hydroxybenzoate; dibasic sodium phosphate heptahydrate; sucrose; citric acid; ethanol; propylene glycol; quinoline yellow; purified water; flavour - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 250 microgram - tablet, uncoated - excipient ingredients: oxidised maize starch; maize starch; magnesium stearate; lactose monohydrate; rice starch - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - ipratropium bromide monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - ipratropium bromide monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - amphotericin b, quantity: 10 mg - lozenge - excipient ingredients: acacia; mannitol; polyvinyl alcohol; saccharin sodium; sodium cyclamate; purified talc; stearic acid; flavour - treatment of candidal infections of the oral and perioral areas including oral thrush, angular cheilitis, denture stomatitis and in other conditions of the mouth, throat and tongue complicated by the overgrowth of candida albicans.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 2 mg - tablet, uncoated - excipient ingredients: sodium benzoate; docusate sodium; maize starch; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate; povidone; microcrystalline cellulose; lactose - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 1 mg - tablet, uncoated - excipient ingredients: indigo carmine; docusate sodium; sodium benzoate; lactose; sodium starch glycollate; povidone; magnesium stearate; maize starch; colloidal anhydrous silica; microcrystalline cellulose - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; lactose; povidone; sodium benzoate; magnesium stearate; microcrystalline cellulose; docusate sodium; sodium starch glycollate; colour - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - labetalol hydrochloride, quantity: 200 mg - tablet, film coated - excipient ingredients: maize starch; magnesium stearate; methyl hydroxybenzoate; lactose monohydrate; hypromellose; propyl hydroxybenzoate; pregelatinised maize starch; titanium dioxide; sunset yellow fcf; purified water; sodium benzoate; industrial methylated spirit - indications as at 24 oct 1996 : treatment of all grades of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - labetalol hydrochloride, quantity: 100 mg - tablet, film coated - excipient ingredients: methyl hydroxybenzoate; lactose monohydrate; maize starch; propyl hydroxybenzoate; hypromellose; magnesium stearate; pregelatinised maize starch; titanium dioxide; sunset yellow fcf; purified water; sodium benzoate; industrial methylated spirit - indications as at 24 oct 1996 : treatment of all grades of hypertension.